Timothy S. Shilton
Chief Executive Officer at ReGen Therapeutics Ltd.
Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Norman Lott | M | 68 |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | 12 years |
W. Roger Rush | M | - |
University of Surrey
| 7 years |
Percy William Cecil Lomax | M | - |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | 13 years |
Keith Corbin | M | 71 |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
Allen Gelberg | M | - |
University of Surrey
| 4 years |
Rick Franklin | M | 78 |
Phairson Medical Ltd.
Phairson Medical Ltd. Miscellaneous Commercial ServicesCommercial Services Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK. | 6 years |
Mark Millett | M | 64 |
University of Surrey
| 4 years |
Kian Wah Siew | M | 65 |
University of Surrey
| 4 years |
Keck Keong Lee | M | 70 |
University of Surrey
| 4 years |
Martin Fry | M | - |
University of Surrey
| 4 years |
Akram-Mark Yassin | M | - |
University of Surrey
| 4 years |
Peter R. Garrod | M | 73 |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
Kian Wah Siew | M | - |
University of Surrey
| 4 years |
Marian L. Kruzel | M | - |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | - |
Ian Martin Collins | M | - |
University of Surrey
| 3 years |
Savvas Pallaris | M | - |
University of Surrey
| 4 years |
Martin J. Small | M | - |
ReGen Therapeutics Plc
ReGen Therapeutics Plc Pharmaceuticals: MajorHealth Technology ReGen Therapeutics Plc develops healthcare nutraceutical and ethical pharmaceuticals. Its principal activity is research and development of a drug product called Colostrinin for the treatment for Alzheimer's disease and other neurological disorders. It also involves in the development of Colostrinin peptides as pharmaceutical drug candidates for the treatment of Alzheimer's disease and obesity. ReGen Therapeutics Plc conducts pharmacokinetic and pharmacodynamic research. The company was founded on February 11, 1998 and is headquartered in London, the United Kingdom. | 13 years |
Didier Cowling | M | 59 |
Phairson Medical Ltd.
Phairson Medical Ltd. Miscellaneous Commercial ServicesCommercial Services Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK. | 4 years |
Patrick John Banks | M | 62 |
Phairson Medical Ltd.
Phairson Medical Ltd. Miscellaneous Commercial ServicesCommercial Services Phairson Medical Ltd. researches and develops novel biopharmaceutical products and devices. The private company is based in London, UK. | 5 years |
Joon Lian Goh | M | 71 |
University of Surrey
| 4 years |
Statistics
Country | Connections | % of total |
---|---|---|
United Kingdom | 20 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Timothy S. Shilton
- Personal Network